Business Wire

NY-CITIGROUP

13.9.2022 20:03:03 CEST | Business Wire | Press release

Share
Citi Private Bank Finds Family Offices’ Priorities Transcend Preserving the Value of Financial Assets and include Fostering Family Unity and Continuity

Citi Private Bank’s Family Office Group today released the results of its 2022 Family Office Survey, capturing the thinking and behaviors of some of the most diverse family offices and ultra-high net worth investors globally. At a time of increasingly broad financial and geopolitical challenges, the report outlines areas of opportunities for potential growth in the year ahead.

Seven predominant themes emerged from the survey: 1) concerns go beyond financial assets, 2) portfolio values declined overall year to date, 3) outlook is positive despite the economic and geopolitical uncertainty, 4) direct investing remains a priority, 5) professionalization of the investment function in family offices continues, 6) readiness to manage family unity and continuity will be key for long-term success, and 7) allocations to sustainable and ESG investments have room to grow.

“Each of our family office clients has a unique need and perspective that helps inform how we can support progress towards their financial goals for generations to come,” says Ida Liu, Global Head of Citi Private Bank. “There is a growing awareness of the dual necessity to prepare wealth for families and families for wealth. And as a trusted partner, Citi Private Bank can help them do that.”

While the top three current economic concerns include inflation, fears of a recession and geopolitical uncertainty, family office executives expressed strong interest in preparing for the future. This includes preserving the value of the family’s assets and preparing the next generation to transition into leadership roles as responsible wealth owners. In fact, leadership successions at the family, family office or trustee levels are among the key transitions that a majority of respondents are expecting to face in the next five years.

“We are thrilled to share this year’s survey highlights, reflecting the urgent need for family offices to plan today for a successful future,” says Hannes Hofmann, the new Global Head of the Family Office Group at Citi Private Bank. “I look forward to working with some of the world’s most diverse and sophisticated family offices.”

Despite the concerns and perhaps a reflection of their sentiment that the market may have bottomed out, there is a high degree of optimism for portfolio returns over the next twelve months, with 80% of the family offices expecting portfolio gains and 62% expecting a 5% or higher increase in portfolio value. As far as asset allocation, public equity represents the lion’s share at 23%, but the attractiveness of real estate and private equity remains, representing 35% of asset allocations combined (20% and 15% respectively).

The 2022 Family Office Survey also found that direct investing remains a primary focus for family offices, with about a third of them allocating between 10% and 20% of their portfolio, while another third allocate more than 30%. Direct investments are split almost evenly between real estate (37%) and operating businesses (33%).

“We were excited to have doubled the number of questions this year to gain more valuable insight into the broad challenges family offices are facing and further understand where they want to go,” says Alexandre Monnier, Global Head of Family Office Services & Network. “In this survey we tried to capture where but also how family offices are investing, such as whether they rely on an investment committee or a board. This information helps further inform our clients on steps their peers are taking to address their needs and meet their goals.”

This year’s survey also showed that the opportunity to translate curiosity about sustainable or ESG investments into action remains significant, as 60% of family offices still have not considered aligning some of their portfolio with these themes or are unsure how they align. Co- or direct investment opportunities, private markets more broadly, and innovative strategies and partnerships demonstrate the greatest potential for ESG-related investments.

This year’s survey was initiated during Citi Private Bank’s seventh annual Family Office Leadership Program held in-person in June 2022 for the first time since the onset of the Covid-19 pandemic. The survey was subsequently released to Citi Private Bank’s global family office clients for input. The survey included over 30 questions aimed at gauging investment sentiment and portfolio actions of clients in the wake of macroeconomic headwinds and market volatility in early 2022. It drew responses from nearly 200 participants, of which 126 were completed and considered for this report.

About Citi Private Bank:
Citi Private Bank is dedicated to serving worldly and wealthy individuals and families, providing customized private banking across borders. With around $500 billion in total client business, the franchise serves clients across 50 cities in over 100 countries. Citi Private Bank helps clients grow and preserve wealth, finance assets, make cash work harder, safeguard assets, preserve legacies, and serve family and family business needs. The firm offers clients products and services covering capital markets, managed investments, portfolio management, trust and estate planning, investment finance, banking and aircraft finance, art advisory and finance, and sports finance.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913006034/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye